Pritumumab
Pritumumab (PTB) is a human monoclonal antibody targeted against glioma.
≈ 1 min read
Pritumumab. encyclopegia.org, snapshot enwiki-001188064451. /a/pritumumab
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pritumumab (PTB) is a human monoclonal antibody targeted against glioma. It works by binding to the ecto-domain of vimentin on the surface of cancer cells. developed by Nascent Biotech. It is in clinical trials for the treatment of glioma.
The FDA granted orphan drug designation in 2015. The target of Pritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV). PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1188064451 under CC BY-SA 4.0; modifications have been made.